CureVac N.V. (CVAC)
CVAC Stock Price Chart
Explore CureVac N.V. interactive price chart. Choose custom timeframes to analyze CVAC price movements and trends.
CVAC Company Profile
Discover essential business fundamentals and corporate details for CureVac N.V. (CVAC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Aug 2020
Employees
825.00
Website
https://www.curevac.comCEO
Alexander Zehnder
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
CVAC Financial Timeline
Browse a chronological timeline of CureVac N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.17, while revenue estimate is $34.59M.
Earnings released on 15 Aug 2025
EPS came in at -$0.30 falling short of the estimated -$0.18 by -66.67%, while revenue for the quarter reached $1.47M , missing expectations by -95.76%.
Earnings released on 20 May 2025
EPS came in at -$0.24 falling short of the estimated -$0.16 by -50.00%, while revenue for the quarter reached $893.00K , missing expectations by -73.25%.
Earnings released on 10 Apr 2025
EPS came in at -$0.15 surpassing the estimated -$0.21 by +28.57%, while revenue for the quarter reached $14.98M , missing expectations by -27.21%.
Earnings released on 12 Nov 2024
EPS came in at $1.50 surpassing the estimated $0.56 by +167.86%, while revenue for the quarter reached $541.68M , beating expectations by +8.23K%.
Earnings released on 15 Aug 2024
EPS came in at -$0.34 falling short of the estimated -$0.26 by -30.77%, while revenue for the quarter reached $15.52M , beating expectations by +159.13%.
Earnings released on 24 Apr 2024
EPS came in at -$0.42 falling short of the estimated -$0.18 by -133.33%, while revenue for the quarter reached $13.29M , beating expectations by +1.78%.
Earnings released on 11 Mar 2024
EPS came in at -$0.42 falling short of the estimated -$0.20 by -110.00%, while revenue for the quarter reached $24.18M .
Earnings released on 14 Nov 2023
EPS came in at -$0.24 surpassing the estimated -$0.26 by +7.69%, while revenue for the quarter reached $17.39M , missing expectations by -41.60%.
Earnings released on 17 Aug 2023
EPS came in at -$0.33 falling short of the estimated -$0.24 by -37.50%, while revenue for the quarter reached $8.27M , missing expectations by -49.46%.
Earnings released on 30 May 2023
EPS came in at -$0.29 matching the estimated -$0.29, while revenue for the quarter reached $7.75M , missing expectations by -44.44%.
Earnings released on 25 Apr 2023
EPS came in at -$0.60 falling short of the estimated -$0.31 by -93.55%, while revenue for the quarter reached $12.59M , missing expectations by -33.06%.
Earnings released on 16 Nov 2022
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%, while revenue for the quarter reached $10.95M , missing expectations by -45.05%.
Earnings released on 18 Aug 2022
EPS came in at -$0.31 falling short of the estimated -$0.26 by -19.23%, while revenue for the quarter reached $21.07M , beating expectations by +12.75%.
Earnings released on 25 May 2022
EPS came in at -$0.08 surpassing the estimated -$0.50 by +84.00%, while revenue for the quarter reached $26.96M , beating expectations by +5.93%.
Earnings released on 28 Apr 2022
EPS came in at -$0.01 surpassing the estimated -$0.57 by +97.87%, while revenue for the quarter reached $46.74M , beating expectations by +890.81%.
Earnings released on 17 Dec 2021
EPS came in at -$0.93 , while revenue for the quarter reached $34.05M .
Earnings released on 18 Nov 2021
EPS came in at -$1.00 falling short of the estimated -$0.85 by -17.61%, while revenue for the quarter reached $26.57M , beating expectations by +124.79%.
Earnings released on 15 Apr 2021
EPS came in at -$0.33 surpassing the estimated -$0.51 by +35.29%, while revenue for the quarter reached $7.36M .
Earnings released on 31 Mar 2021
EPS came in at -$0.72 , while revenue for the quarter reached $11.80M .
Earnings released on 30 Nov 2020
EPS came in at -$0.24 surpassing the estimated -$0.35 by +31.43%, while revenue for the quarter reached $6.06M , missing expectations by -10.67%.
CVAC Stock Performance
Access detailed CVAC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.